The Europe Motion Sickness Treatment Market should witness market growth of 3.0% CAGR during the forecast period (2023-2029).
The motion sickness treatment market is experiencing growth due to various factors, including a rise in the occurrence of motion sickness, an increase in demand for efficient treatments, and an upsurge in research and development efforts in the pharmaceutical industry. The pharmaceutical industry is experiencing growth and innovation in manufacturing motion sickness medications. This is due to the large population that experiences motion sickness, which presents a significant opportunity for market growth.
In recent years, there has been an increase in the number of approved products for motion sickness medication. The rise in the adoption of medications, including transdermal patches and other drugs, can be attributed to the approvals granted for both generic and branded versions. This drives the expansion of the market. Moreover, the increase in consumer knowledge regarding preventative healthcare and the convenience of accessing medications drives the uptake of motion sickness medications. Furthermore, the manufacturers' boost in promotional activities for new products is anticipated to drive their adoption throughout the projected period.
The United Kingdom's over-the-counter (OTC) drugs sector is expected to experience growth in the next few years due to increasing investments and expenses in pharmaceutical products and therapeutics. The UK's OTC drugs industry is expected to experience growth in the coming years due to increased government investment in the pharmaceutical industry and rising consumer demand for advanced and affordable pharmaceutical products. This investment is aimed at promoting local manufacturers and boosting the overall economy. Hence, with the growing adoption of OTC drugs to counter minor health issues to save cost and time for the user, the utilization of OTC-based drugs like antihistamines and anticholinergics will also increase to treat motion sickness and therefore drive the market expansion in Europe.
The Germany market dominated the Europe Motion Sickness Treatment Market by Country in 2022; thereby, achieving a market value of $33.1 Million by 2029. The UK market is estimated to grow at a CAGR of 2.2% during (2023-2029). Additionally, The France market would register a CAGR of 3.8% during (2023-2029).
Based on Drug Class, the market is segmented into Antihistamines, Anticholinergics and Others. Based on Route of Administration, the market is segmented into Oral and Others. Based on Distribution Channel, the market is segmented into Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Viatris, Inc., Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals, Inc., Baxter International, Inc., Novartis AG, Abbott Laboratories, Sun Pharmaceutical Industries Ltd., Zydus Lifesciences Ltd., Prestige Consumer Healthcare, Inc., WellSpring Pharmaceutical Corporation (Avista Capital Partners).
The motion sickness treatment market is experiencing growth due to various factors, including a rise in the occurrence of motion sickness, an increase in demand for efficient treatments, and an upsurge in research and development efforts in the pharmaceutical industry. The pharmaceutical industry is experiencing growth and innovation in manufacturing motion sickness medications. This is due to the large population that experiences motion sickness, which presents a significant opportunity for market growth.
In recent years, there has been an increase in the number of approved products for motion sickness medication. The rise in the adoption of medications, including transdermal patches and other drugs, can be attributed to the approvals granted for both generic and branded versions. This drives the expansion of the market. Moreover, the increase in consumer knowledge regarding preventative healthcare and the convenience of accessing medications drives the uptake of motion sickness medications. Furthermore, the manufacturers' boost in promotional activities for new products is anticipated to drive their adoption throughout the projected period.
The United Kingdom's over-the-counter (OTC) drugs sector is expected to experience growth in the next few years due to increasing investments and expenses in pharmaceutical products and therapeutics. The UK's OTC drugs industry is expected to experience growth in the coming years due to increased government investment in the pharmaceutical industry and rising consumer demand for advanced and affordable pharmaceutical products. This investment is aimed at promoting local manufacturers and boosting the overall economy. Hence, with the growing adoption of OTC drugs to counter minor health issues to save cost and time for the user, the utilization of OTC-based drugs like antihistamines and anticholinergics will also increase to treat motion sickness and therefore drive the market expansion in Europe.
The Germany market dominated the Europe Motion Sickness Treatment Market by Country in 2022; thereby, achieving a market value of $33.1 Million by 2029. The UK market is estimated to grow at a CAGR of 2.2% during (2023-2029). Additionally, The France market would register a CAGR of 3.8% during (2023-2029).
Based on Drug Class, the market is segmented into Antihistamines, Anticholinergics and Others. Based on Route of Administration, the market is segmented into Oral and Others. Based on Distribution Channel, the market is segmented into Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Viatris, Inc., Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals, Inc., Baxter International, Inc., Novartis AG, Abbott Laboratories, Sun Pharmaceutical Industries Ltd., Zydus Lifesciences Ltd., Prestige Consumer Healthcare, Inc., WellSpring Pharmaceutical Corporation (Avista Capital Partners).
Scope of the Study
By Drug Class
- Antihistamines
- Anticholinergics
- Others
By Route of Administration
- Oral
- Others
By Distribution Channel
- Drug Store & Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Viatris, Inc.
- Teva Pharmaceutical Industries Ltd.
- Amneal Pharmaceuticals, Inc.
- Baxter International, Inc.
- Novartis AG
- Abbott Laboratories
- Sun Pharmaceutical Industries Ltd.
- Zydus Lifesciences Ltd.
- Prestige Consumer Healthcare, Inc.
- WellSpring Pharmaceutical Corporation (Avista Capital Partners)
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Europe Motion Sickness Treatment Market by Drug Class
Chapter 4. Europe Motion Sickness Treatment Market by Route of Administration
Chapter 5. Europe Motion Sickness Treatment Market by Distribution Channel
Chapter 6. Europe Motion Sickness Treatment Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- Viatris, Inc.
- Teva Pharmaceutical Industries Ltd.
- Amneal Pharmaceuticals, Inc.
- Baxter International, Inc.
- Novartis AG
- Abbott Laboratories
- Sun Pharmaceutical Industries Ltd.
- Zydus Lifesciences Ltd.
- Prestige Consumer Healthcare, Inc.
- WellSpring Pharmaceutical Corporation (Avista Capital Partners)
Methodology
LOADING...
